A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.
about
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Prodrug applications for targeted cancer therapy.A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.Dual targeting strategies with bispecific antibodies.
P2860
A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A new drug delivery method of ...... orthotopic pancreatic cancer.
@ast
A new drug delivery method of ...... orthotopic pancreatic cancer.
@en
A new drug delivery method of ...... orthotopic pancreatic cancer.
@nl
type
label
A new drug delivery method of ...... orthotopic pancreatic cancer.
@ast
A new drug delivery method of ...... orthotopic pancreatic cancer.
@en
A new drug delivery method of ...... orthotopic pancreatic cancer.
@nl
prefLabel
A new drug delivery method of ...... orthotopic pancreatic cancer.
@ast
A new drug delivery method of ...... orthotopic pancreatic cancer.
@en
A new drug delivery method of ...... orthotopic pancreatic cancer.
@nl
P2093
P2860
P1433
P1476
A new drug delivery method of ...... orthotopic pancreatic cancer.
@en
P2093
Ashok K Saluja
Brad J Stish
Daniel A Vallera
Donald J Buchsbaum
Selwyn M Vickers
Seunguk Oh
P2860
P304
P356
10.1097/MPA.0B013E3181CBD908
P577
2010-08-01T00:00:00Z